Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesLixte Biotechnology Holdings Inc

Lixte Biotechnology Holdings Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-11-06T21:07:25.072946Z
Market Cap
5.20M

Momentum Score

…

Lixte Biotechnology Holdings, Inc. operates as a clinical-stage biopharmaceutical company that uses biomarker technology to identify enzyme targets associated with serious common diseases. The company primarily focuses on inhibitors of protein phosphatase 2A that are used in combination with cytotoxic agents and/or x-ray, immune checkpoint blockers and other cancer therapies. It develops LB-100 that has completed phase I clinical trial for advanced soft tissue carcinoma and small cell lung cancer, as well as is in Phase II clinical trial for ovarian clear cell cancer. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; license agreements with National Institute of Health and Moffitt Cancer Center; and collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
1.58
Low
9.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Lixte Biotechnology Holdings Inc is a small, publicly traded biotechnology company whose publicly available disclosures are limited and which appears focused on developing therapeutic candidates in oncology. Long-term growth may depend on successful clinical trial outcomes, regulatory approvals, licensing or partnership deals and pipeline expansion, and investors may find the company attractive because positive clinical or corporate milestones could materially support long-term value.

Key investment risks include high clinical and regulatory failure probability, limited or no product revenue with significant cash burn that could lead to dilution or urgent financing, reliance on a small number of programs and partners, and competitive and intellectual property uncertainty.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-111.07%
Net Debt
-4.20M
ROCE
-157.99%
Diluted EPS TTM
-2.16

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -6.31M -6.73M -3.26M -2.44M -2.13M
Net income -6.30M -6.74M -3.26M -2.39M -2.13M
Selling general administrative 4.96M 4.98M 2.01M 1.67M 2.10M
Gross profit - - - - 0.00M
Ebit -6.31M -6.72M -3.27M -2.44M -2.15M
Ebitda -6.30M -6.72M -3.26M -2.49M -2.14M
Depreciation and amortization 0.01M 0.00M 0.01M - 0.01M
Operating income -6.31M -6.72M -3.27M -2.49M -2.14M
Other operating expenses 6.31M 6.72M 3.27M 2.49M 2.14M
Interest expense 0.01M 0.01M 0.00M 0.05M 0.00M
Interest income 0.01M 0.00M 0.01M 0.05M 0.00M
Net interest income 0.00M -0.01M 0.00M 0.05M 0.00M
Income tax expense -0.01M 0.01M -0.00M -0.05M -0.01M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 6.31M 6.72M 3.27M 2.49M 2.14M
Cost of revenue - - - - 0.00M
Total other income expense net -0.00M -0.01M 0.00M 0.05M 0.00M
Net income from continuing ops -6.31M -6.73M -3.26M -2.44M -2.13M
Net income applicable to common shares - -6.73M -3.26M -2.44M -2.13M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 4.31M 5.56M 5.09M 5.23M 2.67M
Other current assets 0.03M 0.01M 0.01M 0.01M 0.06M
Total liab 0.31M 0.39M 0.30M 0.22M 0.24M
Total stockholder equity 3.99M 5.17M 4.79M 5.01M 2.43M
Other current liab 0.31M 0.39M 0.30M 0.01M 0.24M
Common stock 0.00M 0.00M 0.00M 0.00M 0.01M
Capital stock 3.50M 3.50M 3.50M 3.50M 3.51M
Retained earnings -48.48M -43.39M -37.08M -30.35M -27.09M
Cash 4.20M 5.35M 4.82M 5.07M 2.60M
Total current liabilities 0.31M 0.39M 0.30M 0.22M 0.24M
Current deferred revenue 0.16M 0.17M 0.08M 0.02M 0.09M
Net debt -4.20M -5.35M -4.82M -5.07M -2.60M
Short term debt 0.31M -0.39M -0.30M - -0.24M
Other stockholder equity 48.98M 45.06M 38.37M 31.86M 26.02M
Total current assets 4.23M 5.56M 5.09M 5.23M 2.67M
Net tangible assets - - 1.29M 1.51M -1.07M
Net receivables - - - - 0.01M
Accounts payable 0.16M 0.23M 0.23M 0.19M 0.14M
Accumulated other comprehensive income -0.00M - - - -
Common stock total equity - - - 3.50M 0.01M
Non currrent assets other 0.08M - - - 0.00M
Non current assets total 0.08M 0.00M 0.00M 0.00M 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Change to liabilities 0.09M 0.10M -0.03M 0.03M -0.16M
Total cash from financing activities 5.14M 3.90M 4.60M 4.60M 4.48M
Change to operating activities - -0.11M -0.09M -0.01M -0.00M
Net income -6.31M -6.73M -3.26M -2.44M -2.13M
Change in cash 0.53M -0.25M 2.47M -1.67M 2.97M
Begin period cash flow 4.82M 5.07M 2.60M 4.27M 1.31M
End period cash flow 5.35M 4.82M 5.07M 2.60M 4.27M
Total cash from operating activities -4.61M -4.14M -2.13M -1.67M -1.51M
Issuance of capital stock 5.14M 3.69M 4.60M 0.00M 4.50M
Change to account receivables - - 0.01M -0.01M -
Sale purchase of stock - - - - 4.48M
Other cashflows from financing activities 5.14M 0.21M -1.10M 2.60M -0.02M
Change to netincome 1.55M 2.60M 1.25M 0.75M 0.79M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.15M -0.01M -0.12M 0.02M -0.16M
Stock based compensation 1.55M 2.60M 1.25M 0.75M 0.79M
Other non cash items -1.55M 2.60M -2.70M -0.00M 0.00M
Free cash flow -4.61M -4.14M -2.13M -1.67M -1.51M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Lixte Biotechnology Holdings Inc

Lixte Biotechnology Holdings, Inc. operates as a clinical-stage biopharmaceutical company that uses biomarker technology to identify enzyme targets associated with serious common diseases. The company primarily focuses on inhibitors of protein phosphatase 2A that are used in combination with cytotoxic agents and/or x-ray, immune checkpoint blockers and other cancer therapies. It develops LB-100 that has completed phase I clinical trial for advanced soft tissue carcinoma and small cell lung cancer, as well as is in Phase II clinical trial for ovarian clear cell cancer. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; license agreements with National Institute of Health and Moffitt Cancer Center; and collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

680 East Colorado Boulevard, Pasadena, CA, United States, 91101

631 830 7092

https://lixte.com

3

Name Title Year Born
Dr. John S. Kovach M.D. Founder, Pres, CEO, Chief Scientific Officer & Chairman 1937
Mr. Robert Neal Weingarten VP & CFO 1952
Mr. Eric J. Forman J.D. VP & COO 1979
Dr. James S. Miser M.D. Chief Medical Officer 1947
Mr. Bastiaan van der Baan M.Sc. President, CEO & Chairman of the Board of Directors 1972

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…